BioCentury | May 30, 2016
Strategy

Taking Takeda global

...Aurora-A ) inhibitor for small cell lung cancer (SCLC). The other Phase IIb programs include TAK-228...
BioCentury | May 19, 2016
Distillery Therapeutics

Therapeutics: Mammalian target of rapamycin (mTOR; FRAP; RAFT1); mTOR complex 1 (mTORC1); mTORC2

...generic mTOR antagonist rapamycin, which targets the protein's FRB domain, conjugated via a linker to TAK-228...
...FRB domain, kinase domain or both domains, the compound decreased viability compared with rapamycin plus TAK-228...
...compound decreased tumor growth with comparable potency to TAK-228. In a mouse xenograft model of TAK-228-resistant...
BioCentury | Apr 15, 2013
Product Development

Genentech's PI3K arsenal

...treat solid tumors. Takeda Pharmaceutical Co. Ltd. also has three clinical stage compounds. MLN0128 ( INK128...
BioCentury | Mar 7, 2013
Distillery Therapeutics

Indication: Cancer

...studies. Exelixis Inc.'s XL388 is in preclinical development for cancer indications. Takeda Pharmaceutical Co. Ltd.'s INK128...
BioCentury | May 7, 2012
Tools & Techniques

Comparing combos quickly

...inhibitor of phosphoinositide 3-kinase (PI3K) alpha ; IPI-145, a dual inhibitor of PI3K delta/gamma; and INK128...
BioCentury | Feb 27, 2012
Product Development

Take your PI(3)K

...Intellikine in January for $190 million up front and up to $120 million in milestones. INK128...
...began partnering discussions two years ago. "We were impressed by how quickly Intellikine was moving INK128...
...perhaps other diseases, according to Curran. Takeda has specific combinations in mind. "Examples include combining INK128...
BioCentury | Jan 2, 2012
Finance

Holiday cheer

...far away. The other half is more of a stretch," said Sofinnova's Mike Powell. Intellikine's INK128...
BioCentury | Jan 2, 2012
Company News

Intellikine, Takeda deal

...$190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128...
BioCentury | Dec 21, 2011
Top Story

Takeda to acquire Intellikine

...$190 million up front and up to $120 million in milestones. Takeda will gain Intellikine's INK128...
BioCentury | Oct 13, 2011
Targets & Mechanisms

Getting fat off PI3Kgamma

...companies plan to use as they move forward with their PI3Kg program. Intellikine's lead compound, INK128...
...is in Phase I testing to treat advanced solid tumors and multiple myeloma (MM). INK128...
Items per page:
1 - 10 of 17